10-QPeriod: Q3 FY1999

ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 1999

Filed November 12, 1999For Securities:LLY

Summary

Eli Lilly & Company's third-quarter 1999 report (filed November 11, 1999) showcases robust top-line growth and improved profitability, driven by strong performance in key therapeutic areas. Net sales increased by 10% year-over-year for the quarter, reaching $2.59 billion, and grew 9% for the first nine months to $7.18 billion. This growth was primarily fueled by strong momentum in Neurosciences, Endocrinology, and Cardiovascular product sales, with notable contributions from flagship products like Zyprexa, Gemzar, and Evista. The divestiture of the PCS health-care-management subsidiary in January 1999 significantly bolstered cash reserves and simplified the company's focus on pharmaceutical innovation. Despite challenges such as declining Prozac sales and ongoing litigation concerns, Eli Lilly demonstrates resilience. The company's strategic focus on high-growth areas, coupled with effective cost management and disciplined R&D investment, positions it for continued success. Significant cash generation from operations and the PCS sale, along with prudent debt management, provides a strong financial foundation. Investors can anticipate continued focus on product development and market expansion, although the company acknowledges potential headwinds from generic competition and legal challenges.

Key Highlights

  • 1Net sales for the third quarter of 1999 increased by 10% to $2.59 billion compared to the prior year, with nine-month sales up 9% to $7.18 billion.
  • 2Strong sales growth was observed in key segments, notably Neurosciences and Endocrinology, driven by products like Zyprexa, Gemzar, and Evista.
  • 3The company completed the divestiture of its PCS health-care-management subsidiary in January 1999, resulting in a gain of $174.3 million and significantly increasing cash and cash equivalents.
  • 4Cash and cash equivalents surged to $3.29 billion at September 30, 1999, up from $1.50 billion at December 31, 1998, primarily due to the PCS sale and operating cash flow.
  • 5Diluted earnings per share for the third quarter were $0.67, an increase from $0.46 in the prior year, indicating improved profitability.
  • 6Research and development expenses increased by 8% for the nine-month period, reflecting continued investment in innovation.
  • 7The company is actively managing potential legal risks, particularly concerning Prozac patent challenges from generic manufacturers, and has established reserves for product liability and environmental matters.

Frequently Asked Questions

Eli Lilly's sales growth is primarily driven by strong performance in key therapeutic areas such as Neurosciences and Endocrinology, with notable contributions from products like Zyprexa, Gemzar, and Evista. The company also benefited from a 10% increase in sales for the third quarter and a 9% increase for the first nine months of 1999.

The divestiture of the PCS health-care-management subsidiary in January 1999 generated a significant gain of $174.3 million and substantially increased Eli Lilly's cash reserves. Cash and cash equivalents rose to $3.29 billion from $1.50 billion, strengthening the company's financial flexibility and allowing for a greater focus on pharmaceutical innovation.

Key risks and challenges include ongoing patent litigation and potential generic competition for Prozac, which has seen sales declines. The company also faces product liability lawsuits and potential environmental liabilities. Additionally, while not detailed extensively in the financial statements, the report notes potential disruptions from Year 2000 (Y2K) preparations and supply chain issues.

Research and Development expenses increased by 1% for the third quarter and 8% for the first nine months of 1999. While overall R&D spending is increasing, the company anticipates that R&D expense growth for the full year 1999 will be at a rate lower than sales growth, partly due to the discontinuation of certain Phase III clinical trials.